Decibel Therapeutics announced a partnership with Invitae, to launch AmplifyTM, a no-charge genetic testing program to screen for the genetic cause of congenital hearing loss in children diagnosed with auditory neuropathy. AmplifyTM is available to individuals who meet the following criteria: Absent or highly abnormal Auditory Brainstem Response (ABR) in both ears; Presence of Distortion Product Otoacoustic Emissions (DPOAE) in at least three frequencies in at least one ear; Less than five years of age.